コラム
Baloxavir (Xofluza) in Japan: Influenza Treatment and Safety
This guide to Baloxavir in Japan covers Xofluza, influenza treatment versus prophylaxis and safety. It separates medicine-specific information from the product and prescription checks needed for an individual consultation.
Our clinic does not currently offer prescriptions for this medicine. This article provides general medicine information.
When researching Xofluza (baloxavir marboxil), distinguish the ingredient, the condition being treated, the formulation and the directions for use. This article explains the uses and safety precautions supported by official documentation. It is not intended for self-diagnosis based only on symptoms or for applying someone else’s prescription or an overseas dosage chart to yourself.
Medical reviewer: Masashi Morita, MD
This influenza medicine inhibits cap-dependent endonuclease, which is needed for viral replication. It is not a medicine that simply lowers fever like an antipyretic. This article explains the medicine to help you understand it. Consult a doctor or pharmacist about individual treatment decisions.
- Ingredient
- Baloxavir
- Use/patient group
- Influenza
- Before use
- Product name, strength, medical conditions and other medicines
Summary and quick-reference table
This influenza medicine inhibits cap-dependent endonuclease, which is needed for viral replication. It is not a medicine that simply lowers fever like an antipyretic. This article explains the medicine to help you understand it. Consult a doctor or pharmacist about individual treatment decisions.
| What to check | Key points |
|---|---|
| Ingredient/product | Xofluza (baloxavir marboxil) |
| Scope of the information | Influenza |
| Individual treatment decisions | Review medical conditions and other medicines with a doctor or pharmacist |
| Deciding whether to use it | Discuss contraindications, other medicines, medical conditions and pregnancy with a doctor or pharmacist |
How the medicine works and its ingredients
This influenza medicine inhibits cap-dependent endonuclease, which is needed for viral replication. It is not a medicine that simply lowers fever like an antipyretic.
Official prescribing information/product documentation (18. Pharmacology).
Approved uses in Japan and the distinction from off-label use
It is used for influenza A and B. In the current Japanese prescribing information, 20 mg tablets and 2% granule sachets are indicated for treatment and prophylaxis, while 10 mg tablets are indicated only for treatment. The same brand name does not mean every strength has the same indications.
Official prescribing information/product documentation (4. Indications, 5. Precautions concerning indications).
Check the formulation and directions for use
It is usually taken as a single dose. The amount depends on age, weight and whether it is being used for treatment or prophylaxis. Do not add a second dose yourself if fever continues. Treatment should start as soon as possible after symptom onset; a doctor decides how to proceed after 48 hours.
Official prescribing information/product documentation (6. Dosage and administration, 7. Precautions concerning dosage and administration).
When treatment may not work well and its limitations
It does not treat bacterial infections or ordinary colds. Prophylaxis requires assessment of eligibility and the timing of contact; it does not replace vaccination or basic infection precautions.
Official prescribing information/product documentation (5. Precautions concerning indications, 8. Important precautions).
After taking the medicine: progress and when to seek care
Assess breathing, fluid intake, consciousness and the course of symptoms as well as fever. If there is breathing difficulty, altered consciousness or inability to drink, seek in-person or emergency care without waiting for an online medicine consultation.
Official prescribing information/product documentation (8. Important precautions).
Side effects and symptoms requiring medical attention
Watch for shock, anaphylaxis and bleeding. Contact a doctor for bloody stools, blood in urine or nosebleeds. Abnormal behavior can occur during influenza regardless of medicine use, so precautions such as preventing falls in minors are necessary.
Official prescribing information/product documentation (8. Important precautions, 11. Adverse reactions).
When it cannot be used and conditions to disclose
Do not use it if you have hypersensitivity to an ingredient. Use in children, during pregnancy or with serious underlying conditions requires an individual assessment.
Official prescribing information/product documentation (2. Contraindications (patients who must not receive the medicine), 9. Precautions in patients with specific backgrounds).
Other medicines, supplements and everyday precautions
Japanese prescribing information reports prolonged prothrombin time after concomitant warfarin use. Tell your doctor or pharmacist about all medicines you take. PMDA 10.2
US FDA labeling warns that simultaneous use with products containing calcium, iron, zinc or other polyvalent cations may lower baloxavir exposure and reduce efficacy. This is information from US labeling; discuss concomitant products with your doctor or pharmacist. US FDA 2.1 / 7.1
Pregnancy and breastfeeding precautions
During pregnancy, therapeutic benefits and risks are assessed. Discuss breastfeeding based on medicine information and the condition. Do not leave fever during pregnancy unassessed.
Storage and maintaining product quality
Store tablets and granules under the room-temperature conditions on the packaging. Do not give leftover medicine to someone else or decide yourself to use it the following season.
Official prescribing information/product documentation (Storage and shelf life, 14. Precautions for administration/use).
Differences from related medicines
Tamiflu is an oral neuraminidase inhibitor taken repeatedly; Inavir is inhaled. Do not choose solely for the convenience of a single dose. Discuss age, ability to inhale, the condition and considerations about resistance.
Official prescribing information/product documentation (4. Indications, 6. Dosage and administration, 18. Pharmacology).
What to discuss with a doctor or pharmacist
Clarify the timing of symptom onset and exposure, underlying conditions, and drinking and breathing status. Distinguish prophylaxis from treatment and discuss whether testing or an in-person consultation is needed.
This article provides general information about the medicine. Our clinic does not currently offer prescriptions for this medicine. Consult a medical institution that manages the relevant symptoms and indications. If sudden breathing difficulty or altered consciousness occurs, seek emergency care without waiting for an article or an online consultation reply.
Points for safer use
- Confirm the route—oral, topical or injection—and the actual product name and strength.
- Distinguish approval in Japan, off-label use and descriptions in overseas documentation.
- Record benefits and side effects together; do not increase the dose yourself or share medicines.
- Tell a healthcare professional about other medicines, supplements, pregnancy, breastfeeding and medical conditions.
Frequently asked questions
For Baloxavir, can anyone take it for prophylaxis if a family member has influenza?
Eligibility for prophylaxis, age and timing after contact must be assessed. The indications for 20 mg tablets or granules differ from those for 10 mg tablets. Do not repurpose medicine available at home.
How does Baloxavir differ from other medicines or products?
Tamiflu is an oral neuraminidase inhibitor taken repeatedly; Inavir is inhaled. Do not choose solely for the convenience of a single dose. Discuss age, ability to inhale, the condition and considerations about resistance.
Can SWIFT prescribe Baloxavir through an online consultation in Japan?
Our clinic does not currently offer prescriptions for this medicine. Discuss its use with the prescribing clinician or an appropriate medical specialty.
Medical reviewer of this article
Dr Masashi Morita
Medical reviewer, Shimbashi Ginza Swift Clinic
- Board-certified specialist and instructor, Japanese Urological Association
- Board-certified specialist, Japan Endocrine Society
- Doctor of Medical Science, Showa University
- Graduate of Showa University School of Medicine
References
- PMDA electronic label (source checked 2026-10-13; primary sources rechecked 2026-10-29)
- US FDA: Xofluza prescribing information (2025)